The effect of gabapentin, an anticonvulsant developed for treating epilepsy but used also in the management of neuropathic pain, has been investigated as an antispastic in SCI (Clark 2002).
Gruenthal et al. (1997; N=28) conducted a randomized, placebo-controlled trial and were able to reveal modest improvements as measured by Ashworth and Likert Scale scores (p=0.044 and 0.013, respectively). Despite the robust study design, no confidence intervals were reported and the sample size was relatively small.
There is limited level 1b evidence from a single RCT that supports the use of gabapentin in SCI-related spasticity. Despite the robust study design and validated outcome measures, no confidence intervals were reported and the sample size was relatively small.
- Gabapentin may be useful in treating SCI spasticity but requires additional confirmatory research.